Nektar's Rezpeg Shows Promise Beyond Eczema, Fueling Bullish Outlook for Immunology Platform
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.